- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01524445
Retrospective Survey of Re-treatment With Bortezomib
11. juni 2012 oppdatert av: Janssen Pharmaceutica N.V., Belgium
Retrospective Evaluation of Re-Treatment With Bortezomib in Subjects With First Relapse After Bortezomib First-Line Therapy
The purpose of this retrospective study is to collect information about patients who received bortezomib as their first chemotherapy and who responded well to it, but who relapsed afterwards and were treated again with bortezomib a second time after a treatment-free period of at least 6 months.
During this non-interventional study (this means that no drug is being tested in this study) the safety and effectiveness (whether it works or not) of bortezomib re-treatment will be evaluated in patients with multiple myeloma.
Only data already mentioned in your clinical file will be collected.
About 100 adult patients will take part in the study
Studieoversikt
Status
Fullført
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
This is an international, multicenter, non-interventional, retrospective study to evaluate the efficacy and safety of bortezomib in 100 adult patients diagnosed with multiple myeloma (MM) who responded to bortezomib as first-line treatment, experienced partial response or better, presented with relapsed disease, and were re-treated (second-line) with bortezomib (for at least 3 cycles) after a treatment-free interruption of at least 6 months.
As this is a non-interventional study, no changes to the current treatment that the patient receives will be required, and no additional treatment will be provided by the company.
The decision of the patients to take part in this study will not have any impact on the care they receive.
All the appropriate treatment-related decisions will have been made by the treating physician(s), and only data available from clinical practice will be collected.
Retrospective data will be collected at a single time point for each patient (the data collection visit).
Each investigator should collect data from patients fulfilling all inclusion and exclusion criteria.
After receiving the signed informed consent form (ICF) from the patient (if required by local regulations), the investigator will start documenting the retrospective data for each patient using electronic data capture (eDC).
After confirmation of the patient's eligibility, the patient's last visit, patient characteristics, predefined risk factors (if available), MM-related data, and first- and second-line bortezomib-related data will be documented in the Case Report Form (CRF).
The patient's status after re-treatment with bortezomib, medical resource utilization data, as well as (serious) adverse drug reactions ([S]ADRs) will be collected.
No blood, urine, or other biological samples will be taken, and no additional investigations will be performed.
the current therapy of the patient will be maintained with no changes
Studietype
Observasjonsmessig
Registrering (Faktiske)
35
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
-
Alexandroupoli, Hellas
-
Athens, Hellas
-
Athens Attica, Hellas
-
Patra, Hellas
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år og eldre (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Prøvetakingsmetode
Ikke-sannsynlighetsprøve
Studiepopulasjon
Clinic; Hospital
Beskrivelse
Inclusion Criteria:
- Has a current diagnosis/was diagnosed with MM or secretory MM
- Was previously treated with bortezomib-containing chemotherapy
- Responded to bortezomib as first-line treatment
- Has been re-treated with bortezomib (at least 3 cycles) due to relapse of the disease (following the first bortezomib treatment), after a treatment-free interruption of at least 6 months
- Completed bortezomib re-treatment at least 2 months ago Exclusion Criteria:
- Was a pregnant or breastfeeding woman while receiving either first-line or second-line treatment with Velcade
Has received bortezomib-containing chemotherapy for the first time following a first relapse or later
- Has participated in a clinical trial in which bortezomib was used as second-line treatment following a relapse after response to Velcade as first-line chemotherapy, and the study data are not publicly available at the time of inclusion in the current study
- Has received bortezomib as first-line therapy and was re-treated with bortezomib after first relapse in the VISTA clinical trial
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
---|---|
bortezomib retreatment
bortezomib retreatment due to relapse Patients who received bortezomib-containing chemotherapy as first-line treatment for MM experienced partial response or better and were re-treated (second-line) with bortezomib (for at least 3 cycles) due to a relapse of the disease after a treatment free interruption of at least 6 months
|
Patients who received bortezomib-containing chemotherapy as first-line treatment for MM, experienced partial response or better, and were re-treated (second-line) with bortezomib (for at least 3 cycles) due to a relapse of the disease after a treatment free interruption of at least 6 months
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
overall response after retreatment
Tidsramme: Day 1
|
overall response after retreatment will be assessed from initial diagnosis to the time of data collection
|
Day 1
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
number of medical care encounters
Tidsramme: Day 1
|
number of medical care encounters are collected retrospectively from initial diagnosis to the time of data collection
|
Day 1
|
duration of medical care encounters
Tidsramme: Day 1
|
duration of medical care encounters are collected retrospectively from initial diagnosis to the time of data collection
|
Day 1
|
duration of hospitalization
Tidsramme: Day 1
|
duration of hospitalizations are collected retrospectively from initial diagnosis to the time of data collection
|
Day 1
|
number and character of diagnostic and therapeutic tests and procedures
Tidsramme: Day 1
|
number and character of diagnostic and therapeutic tests and procedures are collected retrospectively from initial diagnosis to the time of data collection
|
Day 1
|
outpatient medical encounters and treatments
Tidsramme: Day 1
|
outpatient medical encounters and treatments are collected retrospectively from initial diagnosis to the time of data collection
|
Day 1
|
safety and tolerability
Tidsramme: Day 1
|
safety and tolerability will be evaluated based on the collection of serious and non serious adverse drug reactions from initial diagnosis to the time of data collection
|
Day 1
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. mars 2011
Studiet fullført (Faktiske)
1. oktober 2011
Datoer for studieregistrering
Først innsendt
16. juni 2011
Først innsendt som oppfylte QC-kriteriene
1. februar 2012
Først lagt ut (Anslag)
2. februar 2012
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
12. juni 2012
Siste oppdatering sendt inn som oppfylte QC-kriteriene
11. juni 2012
Sist bekreftet
1. juni 2012
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Kardiovaskulære sykdommer
- Vaskulære sykdommer
- Sykdommer i immunsystemet
- Neoplasmer etter histologisk type
- Neoplasmer
- Lymfoproliferative lidelser
- Immunproliferative lidelser
- Hematologiske sykdommer
- Hemoragiske lidelser
- Hemostatiske lidelser
- Paraproteinemier
- Blodproteinforstyrrelser
- Neoplasmer, plasmacelle
- Multippelt myelom
- Antineoplastiske midler
- Bortezomib
Andre studie-ID-numre
- CR018175
- 26866138MMY4053 (Annen identifikator: Janssen CTMS ID)
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Multippelt myelom
-
National Cancer Institute (NCI)Aktiv, ikke rekrutterendeMyelom-multippel | Myelom, plasmacelleForente stater
-
National Cancer Institute (NCI)FullførtMyelom-multippel | Myelom, plasmacelleForente stater
-
National Cancer Institute (NCI)FullførtMyelom-multippel | Myelom, plasmacelleForente stater
-
National Cancer Institute (NCI)AvsluttetMyelom, multippel | Myelom-multippelForente stater
-
Tel-Aviv Sourasky Medical CenterFullførtPlasmacellemyelom | Myelom-multippel | Myelom multippel | Myelom, plasmacelleIsrael
-
National Cancer Institute (NCI)Georgetown University; Hackensack Meridian HealthAvsluttetMyelom-multippel | Myelom, plasmacelle | MyelomatoseForente stater
-
University of ChicagoNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeStage I Myelom | Stadium II multippelt myelom | Stadium III multippelt myelomForente stater, Canada
-
Sidney Kimmel Cancer Center at Thomas Jefferson...FullførtStage I Myelom | Stadium II multippelt myelom | Stadium III multippelt myelomForente stater
-
University of Southern CaliforniaNational Cancer Institute (NCI); Celgene CorporationAvsluttetStage I Myelom | Stadium II multippelt myelom | Stadium III multippelt myelomForente stater
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TilbaketrukketStage I Myelom | Stadium II multippelt myelom | Stadium III multippelt myelom
Kliniske studier på bortezomib retreatment due to relapse
-
Janssen-Cilag International NVFullførtMultippelt myelomFrankrike, Polen, Belgia, Tyskland, Israel, Portugal, Tyrkia, Finland, Sverige, Nederland, Norge
-
Millennium Pharmaceuticals, Inc.Johnson & Johnson Pharmaceutical Research & Development, L.L.C.FullførtNon-Hodgkins lymfomFrankrike, Forente stater, Spania, Korea, Republikken, Australia, Israel, India, Thailand, Kina, Tsjekkisk Republikk, Belgia, New Zealand, Den russiske føderasjonen, Finland, Sør-Afrika, Storbritannia, Italia, Brasil, Ungarn, Puerto... og mer
-
Masonic Cancer Center, University of MinnesotaMillennium Pharmaceuticals, Inc.AvsluttetLymfoproliferativ lidelseForente stater
-
Milton S. Hershey Medical CenterUkjentMantelcellelymfomForente stater
-
University of ArizonaNational Cancer Institute (NCI)FullførtLymfom | Mantelcellelymfom | Indolent lymfom | SLLForente stater
-
Fondazione Italiana Linfomi ONLUSFullførtWaldenstroms makroglobulinemiItalia
-
Northwestern UniversityRobert H. Lurie Cancer CenterFullført
-
Janssen-Cilag G.m.b.HAvsluttet
-
UNC Lineberger Comprehensive Cancer CenterNational Cancer Institute (NCI)Fullført